Skip to content

Book value per share at other companies

Eli Lilly logo
Eli LillyLLY
$34.82+98.9%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$33.20+3.0%
Amgen logo
AmgenAMGN
$16.89+47.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$291.77+10.4%
Janux Therapeutics logo
Janux TherapeuticsJANX
$15.02-8.3%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$23.29+2,285%

Other financials

Income statement

See full
Revenue-
Operating income-$53.7M+2.4%
Net income-$49.7M-2.4%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$75.1M-2.1%
Total debt$2.4M+29.5%
Total equity$408.7M-30.8%
Total assets$403.0M-30.5%

Cash flow

See full
Operating cash flow-$46.0M-6.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.08B+140%
Enterprise value$1.01B+168%

Profitability

See full
Operating margin-358.7%
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio10.3×-1.3×

Where this comes from

Calculated from Cullinan Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed November 7, 2024, on SEC EDGAR. View the filing →

Ask your AI about Cullinan Therapeutics, Inc.'s book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cullinan Therapeutics, Inc.'s book value per share?
Cullinan Therapeutics, Inc. (CGEM) reported book value per share of $10.76 in Q3 2024.
How has Cullinan Therapeutics, Inc.'s book value per share changed year-over-year?
Cullinan Therapeutics, Inc.'s book value per share decreased by 1.9% year-over-year, from $10.97 to $10.76.
What is the long-term trend for Cullinan Therapeutics, Inc.'s book value per share?
Over 3 years (2020 to 2023), Cullinan Therapeutics, Inc.'s book value per share has grown at a 3.0% compound annual growth rate (CAGR), from $10.01 to $10.92.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.